Jounce Therapeutics to Present at Upcoming Investor Conferences in January
Jounce Therapeutics (NASDAQ: JNCE) has announced its participation in two investor conferences in January 2022. The H.C. Wainwright BioConnect Virtual Conference will feature a presentation available on-demand from January 10, 2022, at 7:00 a.m. ET. The 40th Annual J.P. Morgan Healthcare Conference will include a live presentation on January 13, 2022, at 12:00 p.m. ET. Webcasts of both presentations can be accessed via Jounce’s website for 30 days post-event.
Jounce focuses on developing cancer immunotherapies and predictive biomarkers, with key programs including JTX-8064 and vopratelimab in various clinical trials.
- None.
- None.
CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that company management will participate at the following upcoming investor conferences in January:
- H.C. Wainwright BioConnect Virtual Conference: Presentation will be available for on-demand viewing starting on January 10, 2022 at 7:00 a.m. ET.
- 40th Annual J.P. Morgan Healthcare Conference: A live presentation will take place on Thursday, January 13, 2022 at 12:00 p.m. ET.
A webcast of each presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following the presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. JTX-8064 is currently being investigated alone and in combination with pimivalimab (formerly JTX-4014), Jounce’s internal PD-1 inhibitor, in 7 different tumor types in the Phase 1/2 INNATE trial. Jounce’s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce’s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to GS-1811 (formerly JTX-1811), a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.
Investor and Media Contact:
Eric Laub
+1-857-259-3853
elaub@jouncetx.com
FAQ
What are the upcoming investor conferences for Jounce Therapeutics in January 2022?
When will Jounce's presentation at the H.C. Wainwright BioConnect Virtual Conference be available?
What time is Jounce's live presentation at the J.P. Morgan Healthcare Conference?
Where can I find the webcasts of Jounce's conference presentations?
What is the focus of Jounce Therapeutics as a company?
